CURRENT ISSUE
ARCHIVE
ONLINE FIRST
ABOUT THE JOURNAL
INSTRUCTIONS FOR AUTHORS
2/2022 vol. 97
Stats
Get citation
REVIEW PAPER
Guidelines for immunization of children following multisystem inflammatory syndrome in children
Kamila Maria Ludwikowska 1
,
 
Magdalena Okarska-Napierała 2
,
 
Agnieszka Matkowska-Kocjan 1
,
 
Teresa Jackowska 3
,
 
Jacek Wysocki 4,5
,
 
Ernest Kuchar 2
,
 
Jarosław Peregud-Pogorzelski 6
,
 
Leszek Szenborn 1
 
 
 
More details
Hide details
1
Department of Pediatric Infectious Diseases, Wroclaw Medical University, Wroclaw, Poland
 
2
Department of Pediatrics with Clinical Assessment Unit, Medical University of Warsaw, Warsaw, Poland
 
3
Department of Pediatrics, Medical Centre of Postgraduate Education, Warsaw, Poland
 
4
Department of Preventive Medicine, Poznan University of Medical Sciences, Poznan, Poland
 
5
2nd Department of Infectious Diseases, Children’s Hospital in Poznan, Poznan, Poland
 
6
Department of Pediatrics, Pediatric Oncology and Immunology, Pomeranian Medical University, Szczecin, Poland
 
 
Submission date: 2022-04-04
 
 
Final revision date: 2022-04-22
 
 
Acceptance date: 2022-04-22
 
 
Publication date: 2022-06-10
 
 
Pediatr Pol 2022;97(2):81-88
DOI: https://doi.org/10.5114/polp.2022.116576
 
 
Article (PDF)
References (59)
 
KEYWORDS
vaccines
COVID-19
SARS-CoV-2
PIMS-TS
BNT 162b2
 
TOPICS
ABSTRACT
Multisystem inflammatory syndrome in children (MIS-C) is a late complication of SARS-CoV-2 infection, either symptomatic or asymptomatic. The underlying cause is immunological dysregulation, leading to severe inflammatory processes. Children with MIS-C require hospital treatment, the use of immunomodulating drugs, and often intensive care. COVID-19 vaccination is safe and highly effective in preventing not only severe COVID-19, but also MIS-C in adolescents. However, there are no explicit vaccination recommendations for children who underwent MIS-C. We present a summary of current knowledge on vaccinations against COVID-19 in the context of MIS-C. Moreover, we propose guidance concerning vaccinations for children following MIS-C.
REFERENCES (59)
1.
CDC. Multisystem Inflammatory Syndrome in Children (MIS-C). CDC. Available from: https://www.cdc.gov/mis-c/ (lastly accessed: 22 February 2022).
Google Scholar
 
 
2.
Health Policy team. Paediatric multisystem inflammatory syndrome temporally associated with COVID-19 - guidance for clinicians. RCPCH 2020. Available from: https://www.rcpch.ac.uk/resour... (lastly accessed: 22 February 2022).
Google Scholar
 
 
3.
WHO. Multisystem inflammatory syndrome in children and adolescents with COVID-19. Available from: https://www.who.int/publicatio... (lastly accessed: 22 February 2022].
Google Scholar
 
 
4.
Wieteska M, Maj D, Stanicki P. Pediatric inflammatory multisystem syndrome temporally associated with COVID-19 – a novel condition in children and adolescents. Pediatr Pol 2021; 96: 115-120.
Google Scholar
 
 
5.
Belay ED, Abrams J, Oster ME, et al. Trends in geographic and temporal distribution of US children with multisystem inflammatory syndrome during the COVID-19 andemic. JAMA Pediatr 2021; 175: 837-845.
Google Scholar
 
 
6.
Payne AB, Gilani Z, Godfred-Cato S, et al. Incidence of multisystem inflammatory syndrome in children among US persons infected with SARS-CoV-2. JAMA Netw Open 2021; 4: e2116420–e2116420.
Google Scholar
 
 
7.
Holm M, Hartling UB, Schmidt LS, et al. Multisystem inflammatory syndrome in children occurred in one of four thousand children with severe acute respiratory syndrome coronavirus 2. Acta Paediatr 2021; 110: 2581-2583.
Google Scholar
 
 
8.
Wieloukładowy zespół zapalny powiązany z COVID-19. Available from: https://pimsudzieci.pl/ 9lastly accessed: 22 February 2022).
Google Scholar
 
 
9.
Ludwikowska KM, Okarska-Napierała M, Dudek N, et al. Distinct characteristics of multisystem inflammatory syndrome in children in Poland. Sci Reports 2021; 11: 1-13.
Google Scholar
 
 
10.
Godfred-Cato S, Bryant B, Leung J, et al. COVID-19 – associated multisystem inflammatory syndrome in children – United States, March – July 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 1074-1080.
Google Scholar
 
 
11.
Whittaker E, Bamford A, Kenny J, et al. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA 2020; 324: 259-269.
Google Scholar
 
 
12.
Simpson JM, Newburger JW. Multisystem inflammatory syndrome in children in association with COVID-19. Circulation 2020; 142: 437-440.
Google Scholar
 
 
13.
Stopyra L, Kania U, Kwinta P. Inflammatory syndromes including PIMS-TS in children hospitalised in the Malopolska region of Poland in the first wave of the COVID-19 pandemic. Pediatr Pol 2021; 96: 7-15.
Google Scholar
 
 
14.
Tabarkiewicz J, Frączek P, Chen G, Mazur A, Wang J, Jiao F. Advancement of SARS-CoV-2 infection in children. Pediatr Pol 2021; 96: 129-133.
Google Scholar
 
 
15.
Belhadjer Z, Méot M, Bajolle F, et al. Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic. Circulation 2020; 142: 429-436.
Google Scholar
 
 
16.
Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology Clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 2. Arthritis Rheumatol 2021; 73: e13-29.
Google Scholar
 
 
17.
Okarska-Napierała M, Ludwikowska K, Jackowska T, et al. Postępowanie z dzieckiem z wieloukładowym zespołem zapalnym powiązanym z COVID-19 – wytyczne grupy ekspertów przy Polskim Towarzystwie Pediatrycznym. Przegl Pediatr 2021; 50: 1-11.
Google Scholar
 
 
18.
IDSA. SARS-CoV-2 variants. Available from: https://www.idsociety.org/covi... (lastly accessed: 22.February 2022).
Google Scholar
 
 
19.
Kuehn BM. COVID-19 vaccine highly effective against adolescent hospitalizations. JAMA 2021; 326: 2002.
Google Scholar
 
 
20.
Olson SM, Newhams MM, Halasa NB, et al. Effectiveness of BNT 162b2 vaccine against critical covid-19 in adolescents. N Engl J Med 2022; NEJMoa2117995.
Google Scholar
 
 
21.
Zambrano LD, Newhams MM, Olson SM, et al. Effectiveness of BNT 162b2 (Pfizer/BioNTech) mRNA vaccination against multisystem inflammatory syndrome in children among persons aged 12–18 years – United States, July – December 2021. MMWR Morb Mortal Wkly Rep 2022; 71: 52-58.
Google Scholar
 
 
22.
CHMP. Spikevax, INN-COVID-19 mRNA Vaccine (nucleoside modified). Available from: https://www.ema.europa.eu/en/d... (lastly accessed: 22 February 2022).
Google Scholar
 
 
23.
CHMP. Comirnaty, INN-COVID-19 mRNA Vaccine (nucleoside-modified). Available from: https://www.nia.org.pl/wp-cont... (lastly accessed: 22 February 2022).
Google Scholar
 
 
24.
Klein NP, Lewis N, Goddard K, et al. Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA 2021; 326: 1390-1399.
Google Scholar
 
 
25.
Hause AM, Gee J, Baggs J, et al. COVID-19 vaccine safety in adolescents aged 12–17 years – United States, December 14, 2020 – July 16, 2021. MMWR Morb Mortal Wkly Rep 2022; 70: 1053-1058.
Google Scholar
 
 
26.
Lv M, Luo X, Shen Q, et al. Safety, immunogenicity, and efficacy of COVID-19 vaccines in children and adolescents: a systematic review. Vaccines 2021; 9: 1102.
Google Scholar
 
 
27.
Alamer E, Alhazmi A, Qasir NA, et al. Side effects of COVID-19 Pfizer/BioNTech mRNA vaccine in children aged 12–18 years in Saudi Arabia. Vaccines 2021; 9: 1297.
Google Scholar
 
 
28.
Hause AM, Baggs J, Marquez P, et al. COVID-19 vaccine safety in children aged 5–11 years – United States, November 3 – December 19, 2021. MMWR Morb Mortal Wkly Rep 2021; 70: 1755-1760.
Google Scholar
 
 
29.
Bozkurt B, Kamat I, Hotez PJ. Myocarditis with COVID-19 mRNA vaccines. Circulation 2021; 144: 471-484.
Google Scholar
 
 
30.
Oster ME, Shay DK, Su JR, et al. Myocarditis cases reported after mRNA-Based COVID-19 vaccination in the US from December 2020 to August 2021. JAMA 2022; 327: 331-340.
Google Scholar
 
 
31.
Gargano JW, Wallace M, Hadler SC, et al. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the advisory Committee on Immunization Practices – United States, June 2021. MMWR Morb Mortal Wkly Rep 2021; 70: 977-982.
Google Scholar
 
 
32.
Wang M, Wen W, Zhou M, Wang C, Feng Z. Meta-analysis of risk of myocarditis after messenger RNA COVID-19 vaccine. Am J Cardiol 2022; 167: 155-157.
Google Scholar
 
 
33.
Boehmer TK, Kompaniyets L, Lavery AM, et al. Association between COVID-19 and myocarditis using hospital-based administrative data – United States, March 2020 – January 2021. MMWR Morb Mortal Wkly Rep 2022; 70: 1228-1232.
Google Scholar
 
 
34.
Singer ME, Taub IB, Kaelber DC. Risk of myocarditis from COVID-19 infection in people under age 20: a population-based analysis. medRxiv 2021; 2021.07.23.21260998.
Google Scholar
 
 
35.
DMA. Danish Medicines Agency investigates a case of inflammatory condition reported after COVID-19 vaccination. Available from: https://laegemiddelstyrelsen.d... (accessed: 22 February 2022).
Google Scholar
 
 
36.
Nune A, Iyengar KP, Goddard C, Ahmed AE. Multisystem inflammatory syndrome in an adult following the SARS-CoV-2 vaccine (MIS-V). BMJ Case Rep 2021; 14: e243888.
Google Scholar
 
 
37.
Belay ED, Godfred Cato S, Rao AK, et al. Multisystem inflammatory syndrome in adults after SARS-CoV-2 infection and COVID-19 vaccination. Clin Infect Dis 2021; ciab936.
Google Scholar
 
 
38.
Poussaint TY, LaRovere KL, Newburger JW, et al. Multisystem inflammatory-like syndrome in a child following COVID-19 mRNA vaccination. Vaccines (Basel) 2021; 10: 43.
Google Scholar
 
 
39.
Buchhorn R, Meyer C, Schulze-Forster K, Junker J, Heidecke H. Autoantibody release in children after corona virus mRNA vaccination: a risk factor of multisystem inflammatory syndrome? Vaccines 2021; 9: 1353.
Google Scholar
 
 
40.
CDC. Multisystem inflammatory syndrome (MIS). Available from: https://www.cdc.gov/mis/index.... (lastly accessed: 22 February 2022).
Google Scholar
 
 
41.
MZ. Materiały informacyjne dla szpitali i pacjentów dotyczące szczepień przeciwko COVID-19 – szczepienie przeciwko COVID-19 – portal gov.pl. Available from: https://www.gov.pl/web/szczepi... (lastly accessed: 22 February 2022).
Google Scholar
 
 
42.
NHS. Coronavirus (COVID-19) vaccines – NHS. Available from: https://www.nhs.uk/conditions/... (lastly accessed: 22 February 2022).
Google Scholar
 
 
43.
AG. Clinical guidance for COVID-19 vaccine providers. Australian Government Department of Health. Available from: https://www.health.gov.au/init... (lastly accessed: 22 February 2022).
Google Scholar
 
 
44.
ACIP. ACIP COVID-19 vaccine recommendations. CDC. Available from: https://www.cdc.gov/vaccines/h... (lastly accessed: 22 February 2022).
Google Scholar
 
 
45.
WHO. World Health Organization. Coronavirus disease (COVID-19): vaccines. Available from: https://www.who.int/news-room/...) (lastly accessed: 22 February 2022).
Google Scholar
 
 
46.
Bozio CH, Grannis SJ, Naleway AL, et al. Laboratory-confirmed COVID-19 among adults hospitalized with COVID-19 – like illness with infection-induced or mRNA vaccine-induced SARS-CoV-2 immunity – nine states, January – September 2021. MMWR Morb Mortal Wkly Rep 2022; 70: 1539-1544.
Google Scholar
 
 
47.
Gazit S, Shlezinger R, Perez G, et al. Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections. medRxiv 2021; 2021.08.24.21262415.
Google Scholar
 
 
48.
León TM, Dorabawila V, Nelson L, et al. COVID-19 Cases and hospitalizations by COVID-19 vaccination status and previous COVID-19 diagnosis – California and New York, May – November 2021. MMWR Morb Morta l Wkly Rep 2022; 71: 125-131..
Google Scholar
 
 
49.
Anderson EM, Diorio C, Goodwin EC, et al. SARS-CoV-2 antibody responses in children with MIS-C and mild and severe COVID-19. J Pediatric Infect Dis Soc 2021; 10: 669-673.
Google Scholar
 
 
50.
Rostad CA, Chahroudi A, Mantus G, et al. Quantitative SARS-CoV-2 serology in children with multisystem inflammatory syndrome (MIS-C). Pediatrics 2020; 146: e2020018242.
Google Scholar
 
 
51.
Goldblatt D, Fiore-Gartland A, Johnson M, et al. Towards a population-based threshold of protection for COVID-19 vaccines. Vaccine 2022; 40: 306-315.
Google Scholar
 
 
52.
Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021; 27: 1205-1211.
Google Scholar
 
 
53.
ACIP. ACIP timing and spacing guidelines for immunization. CDC. Available from: https://www.cdc.gov/vaccines/h... (lastly accessed: 22 February 2022).
Google Scholar
 
 
54.
ACIP. ACIP altered immunocompetence guidelines for immunizations. CDC. Available from: https://www.cdc.gov/vaccines/h... (lastly accessed: 22 February 2022).
Google Scholar
 
 
55.
Ludwikowska K, Tracewski E, Tracewski P, Szenborn L. Profilaktyka immunologiczna chorób zakaźnych u dzieci z chorobami serca. Available from: https://www.mp.pl/szczepienia/... (lastly accessed: 22 February 2022).
Google Scholar
 
 
56.
Esposito S, Bianchini S, Dellepiane RM, Principi N. Vaccines and Kawasaki disease. Expert Rev Vaccines 2016; 15: 417-424.
Google Scholar
 
 
57.
Sakulchit T, Benseler SM, Goldman RD. Acetylsalicylic acid for children with Kawasaki disease. Can Fam Physician 2017; 63: 607.
Google Scholar
 
 
58.
Matkowska-Kocjan A, Grażyńska E. Szczepienia ochronne u pacjentów z zaburzeniami krzepnięcia. Med Prakt 2021; 4: nn-nn.
Google Scholar
 
 
59.
CDC. ACIP vaccine recommendations. CDC. Available from: https://www.cdc.gov/vaccines/h... (lastly accessed: 22 February 2022).
Google Scholar
 
 
Share
Send by email
RELATED ARTICLE
Long COVID-19 in children: a review of key information
COVID-19 restrictions’ impact on epidemiology of respiratory syncytial virus in south-eastern Poland
The impact of the COVID-19 pandemic on the operation of the Emergency Department at the University Hospital in Opole over 12 months: a retrospective study
Long-COVID symptoms after multisystem inflammatory syndrome in children during different pandemic waves
Thrombosis of the lower right limb in an 11-year-old boy – the first manifestation of systemic lupus erythematosus triggered by SARS-CoV-2 infection
Indexes
 
Keywords index
Topics index
Authors index
Journals System - logo
© 2006-2026 Journal hosting platform by Bentus
Scroll to top